John Y Shin1, Sani H Kizilbash2, Steven Robinson2, Joon H Uhm3, Aminah Jatoi2. 1. 1 Department of Medicine, Mayo Clinic, Rochester, MN, USA. 2. 2 Department of Oncology, Mayo Clinic, Rochester, MN, USA. 3. 3 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: Seizures in patients with glioblastoma are associated with worse quality of life. However, their incidence, clinical characteristics, and prognostic implications are less well characterized. OBJECTIVE: This study was undertaken to provide a contemporary experience along with benchmark data relevant to the above in patients with glioblastoma. It also sought to reexplore improved survival with seizures, as observed by others. METHODS: In this single-institution study, patients with glioblastoma from 2010 through 2014 had their medical records reviewed in detail. RESULTS: Among 122 patients, 58 (48%) had a seizure history. Of these, 67% had more than 1, 41% had generalized seizures, and most received antiseizure medication (most commonly levetiracetam). The median survival for patients with seizures was 1.66 years and 0.87 years for those without (hazard ratio for risk of death with seizures: 0.72; 95% confidence interval: 0.43, 1.21; P = .22 by the log-rank test). CONCLUSION: Seizures are common in patients with glioblastoma and, in contrast to earlier reports, are not associated with a statistically significant improvement in survival.
BACKGROUND:Seizures in patients with glioblastoma are associated with worse quality of life. However, their incidence, clinical characteristics, and prognostic implications are less well characterized. OBJECTIVE: This study was undertaken to provide a contemporary experience along with benchmark data relevant to the above in patients with glioblastoma. It also sought to reexplore improved survival with seizures, as observed by others. METHODS: In this single-institution study, patients with glioblastoma from 2010 through 2014 had their medical records reviewed in detail. RESULTS: Among 122 patients, 58 (48%) had a seizure history. Of these, 67% had more than 1, 41% had generalized seizures, and most received antiseizure medication (most commonly levetiracetam). The median survival for patients with seizures was 1.66 years and 0.87 years for those without (hazard ratio for risk of death with seizures: 0.72; 95% confidence interval: 0.43, 1.21; P = .22 by the log-rank test). CONCLUSION:Seizures are common in patients with glioblastoma and, in contrast to earlier reports, are not associated with a statistically significant improvement in survival.
Entities:
Keywords:
glioblastoma; quality of life; seizures; survival
Authors: Patrick M Flanigan; Arman Jahangiri; Ruby Kuang; Albert Truong; Sarah Choi; Alvin Chou; Jonathan W Rick; Susan M Chang; Annette M Molinaro; Michael W McDermott; Mitchel S Berger; Manish K Aghi Journal: Neurosurgery Date: 2017-11-01 Impact factor: 4.654
Authors: Yahya Ahmadipour; Laurèl Rauschenbach; Alejandro Santos; Marvin Darkwah Oppong; Lazaros Lazaridis; Carlos M Quesada; Andreas Junker; Daniela Pierscianek; Philipp Dammann; Karsten H Wrede; Björn Scheffler; Martin Glas; Martin Stuschke; Ulrich Sure; Ramazan Jabbarli Journal: Neurooncol Adv Date: 2020-11-18